Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,631 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Comparator: Placebo Clear all
Completed Phase 2 Interventional

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

NCT06862791
View directory record Official record
Conditions
Obesity or Overweight
Interventions
AZD9550, AZD6234, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
29
States / cities
Dothan, Alabama • Vestavia Hills, Alabama • Cerritos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 2, 2026, 5:43 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

ENA-001 for Opioid Induced Respiratory Depression

NCT06967259
View directory record Official record
Conditions
Respiratory Depression
Interventions
ENA-001, Placebo Comparator
Drug
Lead sponsor
Enalare Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Miami, Florida • Overland Park, Kansas • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 2, 2026, 5:43 PM EDT
Active, not recruiting Phase 2 Interventional

Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT05510115
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

NCT04459338
View directory record Official record
Conditions
Healthy
Interventions
Exendin-9,39, Saline
Biological · Other
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Proprietary Water on Physiological and Perceptual Responses

NCT05451446
View directory record Official record
Conditions
Hydration, Dehydration
Interventions
proprietary water, Active comparator, Placebo
Dietary Supplement · Other
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 1Phase 2 Interventional

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

NCT00957918
View directory record Official record
Conditions
Parkinson's Disease
Interventions
nicotine, placebo comparator
Drug · Other
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 83 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Not applicable Interventional

"A Clinical Study Investigating the Effectiveness of OTC Scar-management Modalities"

NCT04169490
View directory record Official record
Conditions
Scar, Keloid, Hypertrophic Scar, Cicatrix
Interventions
Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer, Active Comparator Onion Skin Extract Gel (Mederma), Active Comparator Silicone Gel (Kelo-Cote), Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer
Other
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 2 Interventional

Telephone Care Management to Address Sleep Problems in Young Children With Autism

NCT01558180
View directory record Official record
Conditions
Autism Spectrum Disorders, Insomnia
Interventions
Telephone Care Management, Usual Care
Behavioral
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Years to 6 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Sep 2, 2026, 5:43 PM EDT
Terminated Phase 2 Interventional Results available

Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

NCT02824913
View directory record Official record
Conditions
Dry Eye Disease
Interventions
P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

NCT04676646
View directory record Official record
Conditions
Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
Interventions
Sodium zirconium cyclosilicate, Placebo, Spironolactone
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Fairhope, Alabama • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 2, 2026, 5:43 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

NCT06619990
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
XmAb942, Placebo
Biological · Drug
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
29
States / cities
Scottsdale, Arizona • Bradenton, Florida • Brandon, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

NCT01015118
View directory record Official record
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms
Interventions
Placebo, Paclitaxel, BIBF 1120, Carboplatin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
33
States / cities
Tucson, Arizona • Long Beach, California • Santa Rosa, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 2Phase 3 Interventional

Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes

NCT00143520
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Rivoglitazone, Pioglitazone, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
74
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 71 more
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Sep 2, 2026, 5:43 PM EDT
Withdrawn Phase 2 Interventional

Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes

NCT01477476
View directory record Official record
Conditions
Type I Diabetes
Interventions
Anakinra, Placebo Comparator
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 2, 2026, 5:43 PM EDT
Terminated Early Phase 1 Interventional

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

NCT03507374
View directory record Official record
Conditions
Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee

NCT02205814
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Fasitibant- low dose, Fasitibant- intermediate dose, Fasitibant- high dose, Placebo comparator
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
40 Years to 80 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Tucson, Arizona • Englewood, Colorado • DeLand, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery

NCT02953587
View directory record Official record
Conditions
Obesity
Interventions
Oral Glucose Tolerance Test (OGTT), Human Ghrelin, Saline
Procedure · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Osteopathic Manipulative Therapy on Hip Range of Motion

NCT06644989
View directory record Official record
Conditions
Runners
Interventions
Spencer Technique, Sham (No Treatment)
Procedure · Other
Lead sponsor
Lake Erie College of Osteopathic Medicine
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

NCT04211389
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
ARQ-151 0.3% cream, ARQ-151 vehicle cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Scottsdale, Arizona • Beverly Hills, California • Encino, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Sep 2, 2026, 5:43 PM EDT
Withdrawn Phase 2 Interventional

IUD and Norethindrone Acetate for Treatment of Endometriosis

NCT04948489
View directory record Official record
Conditions
Endometriosis
Interventions
norethindrone acetate (NETA), Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 24 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

Desvenlafaxine vs. Placebo Treatment of Chronic Depression

NCT01537068
View directory record Official record
Conditions
Dysthymic Disorder, Dysthymia, Chronic Depressive Disorder
Interventions
Desvenlafaxine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
20 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Early Phase 1 Interventional Results available

Effects of Flavors on Nicotine Reinforcement in Smokers

NCT03243630
View directory record Official record
Conditions
Nicotine Dependence
Interventions
IV nicotine, Menthol flavor, green apple, green apple and menthol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 30 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nutritional Intervention for Age-related Muscular Function and Strength Losses-Study 2

NCT02043171
View directory record Official record
Conditions
Sarcopenia
Interventions
Placebo, HMB plus Vitamin D, Non-Exercise, Exercise
Dietary Supplement · Drug · Behavioral
Lead sponsor
Metabolic Technologies Inc.
Industry
Eligibility
60 Years and older
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 10, 2019 · Synced Sep 2, 2026, 5:43 PM EDT
Recruiting Phase 2 Interventional

4-Aminopyridine to Treat Skin Burns

NCT06596434
View directory record Official record
Conditions
Burns, Second Degree Burn, Wounds and Injuries
Interventions
Drug: 4-Aminopyridine, Placebo
Drug · Other
Lead sponsor
John Elfar
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 2, 2026, 5:43 PM EDT